印度疫苗药物警戒:当前背景与未来展望。
Vaccine pharmacovigilance in India: Current context and future perspective.
机构信息
Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
出版信息
Indian J Pharmacol. 2019 Jul-Aug;51(4):243-247. doi: 10.4103/ijp.IJP_53_19.
Pharmacovigilance of vaccines is of paramount importance to promote the safe use of vaccines among their recipients. India launched the Adverse Events Following Immunization (AEFI) surveillance program in 1986 for monitoring suspected adverse events following immunization and since then, the AEFI surveillance guideline has been updated periodically, with the latest being in 2015. The successful AEFI surveillance program in India required the concerted effort of all stakeholders such as National AEFI Secretariat, National Technical Collaborating Centre, Central Drug Standard Control Organization, marketing authorization holder, and health-care professionals.
疫苗的药物警戒对于促进疫苗在接种者中的安全使用至关重要。印度于 1986 年启动了疫苗接种后不良事件(AEFI)监测计划,以监测疑似疫苗接种后不良事件,此后,AEFI 监测指南定期更新,最近一次更新是在 2015 年。印度成功的 AEFI 监测计划需要国家 AEFI 秘书处、国家技术合作中心、中央药物标准控制组织、上市许可持有人和医疗保健专业人员等所有利益相关者的共同努力。